#USA #Portland #Protein Engineering #NSF Grant #Caravel Bio

Caravel Bio's Significant Leap in Protein Engineering

Caravel Bio, a pioneering company in the field of biomolecular engineering, has recently made headlines for securing a substantial grant from the National Science Foundation (NSF) worth $1,246,984. This funding marks a pivotal milestone for Caravel as it responds to the urgent need for innovative approaches in protein engineering that can stimulate economic growth and enhance public health.

Overview of the NSF Grant

The NSF has awarded this grant under its Small Business Innovation Research (SBIR) Phase II program, a competitive initiative that supports small businesses in advancing scientific research and commercialization. Alarmingly, only 5% of applicants have been successful in obtaining this grant in the last decade, underscoring the significance of Caravel's achievement. The financial backing will facilitate the development and scaling of new proteins with previously unutilized chemistries. This approach is expected to redefine the capabilities within the biotechnology sector, promoting the design and manufacturing of proteins that nature typically does not produce.

Accelerating Discovery Through Technology

The innovative platform developed by Caravel is engineered to conduct parallel biological experimentation on an unprecedented scale. This technology allows the testing of millions of protein variants simultaneously, generating extensive datasets crucial for artificial intelligence (AI) applications in protein design. By harnessing this data, Caravel aims to fast-track the movement from laboratory findings to real-world applications, ultimately yielding products that can improve human health while also addressing environmental concerns.

Trevor Nicks, PhD and the founder of Caravel, articulated a pressing motivation behind the company's mission: the inefficiency in conventional biomolecular engineering processes, which often demand exorbitant amounts of funding and time. "I was really exhausted by the inability of the work I and my peers were doing, all with the best intentions, to actually improve the world without spending hundreds of millions of dollars,” he emphasized. With this funding, Caravel is positioned to significantly reduce testing costs and enhance the speed of data collection, making protein engineering more accessible and efficient.

Bridging Gaps in Protein Engineering

One core challenge faced in protein engineering is the limited use of the 20 amino acids that form the foundation of most proteins available today. However, there exists a rich diversity of additional amino acids that could be utilized to create novel products with extraordinary benefits. For instance, the well-known drug Ozempic effectively enhances stability using a non-canonical amino acid. By implementing a comprehensive design-build-test workflow, Caravel is poised to exploit these alternative amino acids.

Recent Milestones and Future Directions

Since securing its Phase I grant in 2024, Caravel has made impressive strides in translating its laboratory-stage innovations into practical partnerships and increased funding avenues. The company was formally launched in October 2025, concurrent with receiving a $7.8 million award from the NSF. Additionally, Caravel joined the Shell GameChanger program to develop ultra-stable enzymes and achieved a remarkable stabilization enhancement of 12-fold within just six months.

In both unique applications of science and collaborations with leading academic and industrial institutions such as Avery Bio, Caltech, and Oregon State University, Caravel is rapidly expanding its network to fuel further research and development.

Under Phase II, the focus will shift toward broadening their platform to encompass various enzyme types, addressing the needs of current clientele while preparing for pilot testing of innovative protein products in diverse applications ranging from DNA writing to carbon capture.

Leadership Changes to Enhance Strategy

In conjunction with the grant announcement, Caravel has brought Michał Jastrzębski on board as the new Chief Technology Officer (CTO). His extensive experience in technology and previous work with AI in biological contexts position him to drive Caravel's agenda forward. Jastrzębski’s aim is to leverage AI to streamline the protein design process, ensuring it operates on a scale previously deemed unattainable.

"I’ve seen firsthand how much AI in biology is still held back by a lack of the right data, not a lack of ambition," remarked Jastrzębski. His participation represents a strategic evolution for Caravel as it seeks to dominate the upcoming era of protein engineering innovation.

Conclusion

The recent $1.2 million NSF grant awarded to Caravel Bio signifies a major advancement in the biotechnology landscape. By championing a new model for biomolecular engineering, Caravel is not only adeptly addressing critical needs but is also paving the way for breakthroughs that could yield substantial benefits for society as a whole. With continuous investment in and development of their pioneering platform, the future resonates with promise and transformative potential.